KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance.
BACKGROUND
The transcriptional regulator in embryonic development, KAP1, has been proved could promote cell proliferation and metastatic progression in a variety of human cancers. However, the role of KAP1 in hepatocellular carcinoma (HCC) remains unclear. The purpose of this study is to investigate the relationship of KAP1 expression with the progression and prognosis of HCC.


METHODS
We measured the expression level of KAP1 in both human hepatoma cell lines and HCC tissues obtained from HCC patients by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot. Furthermore, the effect of KAP1 expression on hepatoma cell proliferation was investigated through KAP1 knock-down strategy. Besides that, the correlation between KAP1 expression and HCC progression was analyzed.


RESULTS
KAP1 overexpression was proved broadly existed in the human hepatoma cell lines. Furthermore, down-regulate the expression of KAP1 by specific siRNA could inhibit cell proliferation which was partly originated from the activation of p53 mediated signal pathway. Moreover, comparisons between the cancer tissues and noncancerous tissues proved the expression level of KAP1 was significant higher in tumor tissues obtained from HCC patients. In addition, KAP1 overexpression was significantly correlated with tumor size and tumor stage and also a predictor for poor prognosis of HCC patients.


CONCLUSIONS
Our results presented here demonstrate that KAP1 plays an important role in HCC and could be regarded as a valuable biomarker for tumor diagnosis and prognosis prediction, as well as a potential target for the treatment of HCC.
Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Yanying
Y
Wang
Department of Neurosurgery, Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China.
Jianxin
J
Jiang
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.|Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Qun
Q
Li
Department of Ultrasonography, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Hong
H
Ma
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. zengguangxu2008@yeah.net.
Zengguang
Z
Xu
Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. gaoyon@hotmail.com.|Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. gaoyon@hotmail.com.
Yong
Y
Gao
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics; D018450:Disease Progression; D005260:Female; D015870:Gene Expression; D006801:Humans; D008099:Liver / Q000737:chemistry; D008113:Liver Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012097:Repressor Proteins / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D000076183:Tripartite Motif-Containing Protein 28; D047368:Tumor Burden
D014408:Biomarkers, Tumor; D012097:Repressor Proteins; C101116:TRIM28 protein, human; D000076183:Tripartite Motif-Containing Protein 28
Biomarker; Hepatocellular carcinoma; KAP1; Prognosis